Key facts
- It has raised $38.0M; the latest was Later Stage VC ($18.0M) in Jan 2025.
- Notable investors include Tony Robbins.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for EVOQ.
- ·The full record, as it builds
Funding rounds
No funding rounds for EVOQ. are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EVOQ.
Developer of an antimicrobial technology designed to create precise novel product outcomes for numerous applications and for multiple drug administration pathways. The company produces customized and earth-friendly nanoparticles, with proven potential in biotech, energy, textiles, additive manufacturing, agriculture, and more, enabling pharmaceutical companies to produce environmentally safe, stable, and reliable short-bond nanoparticles.
- Sector
- Materials and Resources
- HQ
- Salt Lake City, UT, United States
- Founded
- 2011
- Employees
- 24
- Website
- evoqmm.com/
- Ownership
- Privately Held (backing)
EVOQ. doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EVOQ. shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EVOQ. in its N-PORT filings yet. We sweep new filings monthly.